Leqembi sales inch higher; Spark’s pivot leads to layoffs
Bio Pharma Dive
JULY 12, 2024
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.
Merck reports rise in group net sales in fiscal 2022
Pharmaceutical Technology
MARCH 2, 2023
Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.
Sales 
245
245 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS
Pharmaceutical Technology
JANUARY 31, 2023
Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). uniQure will also provide tiered royalties ranging from mid-single digits to low double digits on the net sales.
Gene Therapy 277
277 
Alteogen signs global license deal with Sandoz
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.
Licensing 130
130 
Tay Therapeutics and VYNE sign licensing deal for oral BET inhibitor
Pharmaceutical Technology
MAY 3, 2023
Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.
Licensing 130
130 
Kite and Daiichi Sankyo update cell therapy licensing agreement
Pharmaceutical Technology
DECEMBER 8, 2022
The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K. The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology.
Licensing 305
305 
After setbacks, a gene therapy company mulls a sale
Bio Pharma Dive
APRIL 28, 2022
Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs.
Gene Therapy 267
267 
TherapeuticsMD and Mayne sign product licensing agreements
Pharmaceutical Technology
DECEMBER 5, 2022
Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US. TherapeuticsMD will also get a 20-year royalty stream linked to Mayne’s net product sales.
Licensing 130
130 
Biogen licenses Denali’s amyloid beta programme for Alzheimer’s
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Denali is also expected to receive potential development and commercial milestone payments upon achieving certain milestones, along with royalties based on the future net sales of the drug.
Licensing 130
130 
UniQure sells royalty rights to hemophilia gene therapy
Bio Pharma Dive
MAY 15, 2023
The Dutch biotech sold a portion of royalties owed by CSL Behring on sales of Hemgenix, adding to a cash pile it has built since out-licensing the treatment.
Gene Therapy 300
300 
Takeda signs licensing agreement with HUTCHMED for fruquintinib
Pharmaceutical Technology
JANUARY 23, 2023
As per the terms of the agreement, HUTCHMED will receive an upfront payment of $400m on the closing of the deal, along with additional potential payments of up to $730m in regulatory, development and commercial sales milestones and royalties on net sales. The submission is planned to be completed in the first half of this year.
Licensing 130
130 
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Pharmaceutical Technology
APRIL 25, 2023
German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. Tiered royalties on net sales are also included in the deal. FAP-2286 is being investigated as a peptide-targeted radionuclide therapy.
Licensing 130
130 
Bio-Thera and Biomm enter licensing deal for ustekinumab biosimilar
Pharmaceutical Technology
JUNE 19, 2023
Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. The company stated that the collaboration will use the local presence, sales and marketing capabilities of Biomm in Brazil.
Licensing 130
130 
Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader
Pharmaceutical Technology
MARCH 21, 2023
Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.
Protein 130
130 
Shionogi and MPP enter Covid-19 antiviral licensing deal
Pharmaceutical Technology
OCTOBER 4, 2022
Shionogi will waive royalty payments on product sales in all countries under this deal as long as Covid-19 is listed by the World Health Organization as a Public Health Emergency of International Concern. The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.
Licensing 147
147 
Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products
BioTech 365
APRIL 14, 2021
Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.
Sales 52
52 
Pure Extracts Submits Application to Health Canada for Sales License
BioTech 365
FEBRUARY 22, 2021
Pure Extracts Submits Application to Health Canada for Sales License Pure Extracts Submits Application to Health Canada for Sales License VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure … Continue reading →
Licensing 40
40 
Moderna Q1 reveals COVID-19 vaccine sales stats: Biologics License Application to be submitted this month
BioPharma Reporter
MAY 6, 2021
The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform.
Licensing 97
97 
Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch
BioTech 365
MARCH 16, 2021
Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch –Company Introduces Celebrity Wellness Expert Harley Pasternak as Advisor VANCOUVER, British Columbia, … Continue reading →
Licensing 40
40 
#news #biotech Pragmatism prevails for Dicerna as it looks to out-license the sales work for mixed bag nedosiran
BioTech 365
AUGUST 10, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pragmatism prevails for Dicerna as it looks to out-license the sales work for mixed bag nedosiran.Pragmatism prevails for Dicerna as it looks to out-license the sales work … Continue reading →
Licensing 40
40 
Emergence Therapeutics licenses ADC technology platform in $360M deal
BioPharma Reporter
SEPTEMBER 6, 2022
Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.
Licensing 52
52 
With J&J settlement, Biocon Biologics gets a license to challenge Stelara in the US
Fierce Pharma
FEBRUARY 29, 2024
exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie. As Johnson & Johnson's U.S.
Licensing 108
108 
Lava fires up a $700m cancer licensing deal with Seagen
pharmaphorum
SEPTEMBER 27, 2022
While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. The post Lava fires up a $700m cancer licensing deal with Seagen appeared first on.
Licensing 109
109 
Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B
Bio Pharma Dive
APRIL 13, 2022
Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.
Drug Delivery 141
141 
Centre puts onus on SLAs to take action against e-pharmacies for violation of D&C Act and Rules
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 23, 2023
With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.
Pharmacy 158
158 
More firms join litigation against Central govt on FDC ban
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 16, 2023
At least seven more pharma companies and a federation of pharma manufacturers have approached the Delhi High Court against the Central Government’s order in the beginning of June prohibiting manufacturing, distribution and sale of 14 fixed dose combinations (FDCs) licensed prior to the year 1988.
Pharma Companies 155
155 
Delhi HC grants 10 days’ time to Govt to file counter affidavit on petitions against ban of 14 FDCs
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 11, 2023
The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharma companies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]
Pharma Companies 148
148 
Stealth and Pharmanovia partner for commercialisation of elamipretide
Pharmaceutical Technology
MAY 31, 2023
Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome.
Licensing 245
245 
Akili adds to ADHD gaming range with £37m TALi licensing deal
pharmaphorum
AUGUST 18, 2021
Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital. . TALi is also in line for royalties on sales.
Licensing 64
64 
Sobi bolsters blood division via $435m ADC licensing deal
pharmaphorum
JULY 8, 2022
Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.
Licensing 52
52 
Fierce Pharma Asia—Eisai eyes Leqembi surge; Takeda nabs Alzheimer's drug option; BIOSECURE Act advances
Fierce Pharma
MAY 17, 2024
Following a reportedly bullish assessment from Medicare, Eisai has projected a significant sales increase for Leqembi. Eisai has projected a significant sales increase for Leqembi. Takeda put down $100 million upfront for an option to license an anti-amyloid vaccine from AC Immune.
Sales 88
88 
Valneva, LimmaTech ally on quest for first Shigella vaccine
pharmaphorum
AUGUST 1, 2024
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)
Vaccination 101
101 
China’s NMPA grants priority review status for Ocumension’s Zerviate NDA
Pharmaceutical Technology
MAY 1, 2023
The NDA is supported by the data package licensed to Ocumension by Nicox as well as the Phase III clinical trial in China. Nicox granted exclusive license to Ocumension to develop and commercialise Zerviate in China and most of the Southeast Asian markets.
Licensing 162
162 
GSK sees £20bn peak sales potential in late-stage pipeline
pharmaphorum
JUNE 23, 2021
GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions. mRNA ambitions.
Sales 88
88 
Eisai joins the ADC golden rush
Pharmaceutical Technology
MAY 12, 2023
BlissBio has the potential to earn up to $2bn in commercial milestone payments, as well as royalties on sales if Eisai exercises its option to license the drug. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.
Clinical Trials 162
162 
Gilead licenses Jounce immunotherapy for $800m
pharmaphorum
SEPTEMBER 2, 2020
Jounce could also receive up to $685 million in future clinical, regulatory and commercial milestone payments, as well as royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. The post Gilead licenses Jounce immunotherapy for $800m appeared first on.
Licensing 66
66 
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
The Pharma Data
JANUARY 12, 2021
13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. ,
Licensing 52
52 
AstraZeneca forges licensing agreement with Redx Pharma
The Pharma Data
AUGUST 5, 2020
AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Redx is also eligible to receive up to $360m in additional payments, dependent on development, regulatory and commercial milestones, as well as tiered royalties on any future sales.
Licensing 52
52 
Bayer grows sales and earnings significantly
The Pharma Data
NOVEMBER 9, 2021
Group sales rise by 14.3 percent to 2.089 billion euros / Crop Science reports strong increase in sales and earnings / Pharmaceuticals and Consumer Health again post considerable sales growth / Core earnings per share advance by 29.6 percent (Fx & portfolio adj.) percent to 1.05
Sales 52
52 
Total Dental Health ebook sales page | Health Guru Mike
The Pharma Data
MAY 13, 2021
Product Name: Total Dental Health ebook sales page | Health Guru Mike. Click here to get Total Dental Health ebook sales page | Health Guru Mike at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.
Sales 52
52 
Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug
pharmaphorum
NOVEMBER 10, 2021
The drug was the first in the oral CGRP inhibitor class to get an prevention indication approved by the FDA in May, and that has helped accelerate its rollout, bringing in $336 million in US sales for Biohaven so far this year. The post Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug appeared first on.
Licensing 52
52 
Let's personalize your content